ctl019 transduced cells
Cell therapyexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Aug 14, 2014 (NCT02228096)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetTissue restoration
Tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous ctl019 transduced cells
- ctl019 transduced cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03876769 | Phase 2 | Jun 24, 2019 | National Cancer Institute (NCI), Novartis |
| NCT03123939 | N/A | Apr 13, 2017 | Novartis |
| NCT02167360 | Phase 2 | Jun 1, 2016 | University of Pennsylvania |
| NCT02445248 | Phase 2 | Jul 29, 2015 | Novartis |
| NCT02435849 | Phase 2 | Apr 1, 2015 | Novartis |
| NCT02228096 | Phase 2 | Aug 14, 2014 | Novartis, University of Pennsylvania |
| NCT03601442 | N/A | — | Novartis |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 6 | 6 | 2 | 2014 |
| University of Pennsylvania | Academic/Hospital | 2 | 1 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1